When using daratumumab in the setting of post-transplant red cell aplasia or post-transplant immune-mediated cytopenias, do you hold the drug for certain ANC parameters?
1 Answer
Mednet MemberInvited Expert
Pediatric Hematology/Oncology · CWRU School of Medicine
Answered on
Typically, we do not hold until below ANC 500.
Join for free or sign in to see the full answer